The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura

BMC Medicine

Lyn R Griffiths³  John MacMillan²  James Sundholm³  Micky Ovcaric³  Rod A Lea¹ 

[1] The Institute of Environmental Science and Research Ltd. Wellington, New Zealand;Queensland Clinical Genetics Service, Royal Children's Hospital, Queensland, Australia;Genomics Research Centre, School of Health Science, Griffith University, Queensland, Australia

关键词: variant;    gene;    MTHFR;    association;    migraine;   

Others  :  1130806
DOI  :  10.1186/1741-7015-2-3

 received in 2003-10-01, accepted in 2004-02-12,  发布年份 2004

【 摘 要 】

Background

The C677T variant in the methylenetetrahydrofolate reductase (MTHFR) gene is associated with increased levels of circulating homocysteine and is a mild risk factor for vascular disease. Migraine, with and without aura (MA and MO), is a prevalent and complex neurovascular disorder that may also be affected by genetically influenced hyperhomocysteinaemia. To determine whether the C677T variant in the MTHFR gene is associated with migraine susceptibility we utilised unrelated and family-based case-control study designs.

Methods

A total of 652 Caucasian migraine cases were investigated in this study. The MTHFR C677T variant was genotyped in 270 unrelated migraine cases and 270 controls as well as 382 affected subjects from 92 multiplex pedigrees.

Results

In the unrelated case-control sample we observed an over-representation of the 677T allele in migraine patients compared to controls, specifically for the MA subtype (40% vs. 33%) (χ² = 5.70, P = 0.017). The Armitage test for trend indicated a significant dosage effect of the risk allele (T) for MA (χ² = 5.72, P = 0.017). This linear trend was also present in the independent family-based sample (χ² = 4.25, P_adjusted = 0.039). Overall, our results indicate that the T/T genotype confers a modest, yet significant, increase in risk for the MA subtype (odds ratio: 2.0 – 2.5). No increased risk for the MO subtype was observed (P > 0.05).

Conclusions

In Caucasians, the C677T variant in the MTHFR gene influences susceptibility to MA, but not MO. Investigation into the enzyme activity of MTHFR and the role of homocysteine in the pathophysiology of migraine is warranted.

【 授权许可】

   
2004 Lea et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for the headache disorders, cranialneuralgias and facial pain. Cephalalgia 1988, 8(Suppl):1-96.
• [2]Russell MB, Olesen J: Increased familial risk and evidence of genetic factor in migraine. BMJ 1995, 311(7004):541-4.
• [3]Honkasalo ML, Kaprio J, Winter T, Heikkila K, Sillanpaa M, Koskenvuo M: Migraine and concomitant symptoms among 8167 adult twin pairs. Headache 1995, 35:70-78.
• [4]Larsson B, Bille B, Pedersen NL: Genetic influence in headaches: a swedish twin study. Headache 1995, 35:513-519.
• [5]Goadsby PJ: Current concepts of the pathophysiology of migraine. Neurol Clin 1997, 15(1):27-42.
• [6]Ferrari M: Migraine. The Lancet 1998, 351:1043-1051.
• [7]Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alperovitch A: Association between migraine and endothelin type A receptor (ETA-231 A/G) gene polymorphism. Neurology 2001, 22(56(10)):1273-7.
• [8]Harker LA, Ross R, Slichter SJ, Scott CR: Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976, 58:731-741.
• [9]Wall RT, Harlan JM, Harker LA, Striker GE: Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980, 18:113-121.
• [10]Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993, 91:308-318.
• [11]Cooke JP, Tsao PS: Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 1994, 14:653-655.
• [12]Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, et al.: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996, 98:24-29.
• [13]Hering-Hanit R, Gadoth N, Yavetz A, Gavendo S, Sela B: Is blood homocysteine elevated in migraine. Headache 2001, 41:779-781.
• [14]Bouassira D, Bars DL, Villanueva L: Heterotopic activation of A delta and C fibres triggers inhibition of trigeminal and spinal convergent neurones in the rat. J Physiol 1987, 389:301-317.
• [15]Storer RJ, Goadsby PJ: Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997, 120:2171-2177.
• [16]Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydofolate reductase. Nat Genet 1995, 10:111-113.
• [17]Goyette P, Summer JS, Milos R, Ducan AM, Rosenblatt DS, Matthews RG, Rozen R: Human methylenetetrahydrofolate reductase isolation of cDNA, mapping and mutation identification. Nat Genet 1994, 7:195-200.
• [18]Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325(7374):1202.
• [19]Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P: Elevated plasma homocysteine concentrations as a possible independent risk factor for stroke. Stroke 1990, 21:572-576.
• [20]Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL: Homocysteine, MTHFR 677C-->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002, 59(4):529-36.
• [21]Schwaag S, Nabavi DG, Frese A, Husstedt IW, Evers S: The association between migraine and juvenile stroke: a case-control study. Headache 2003, 43(2):90-5.
• [22]Donaghy M, Chang CL, Poulter NJ: Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. Neurol Neurosurg Psychiatry 2002, 73(6):747-50.
• [23]Tzourio C, Iglesias S, Hubert JB, Visy JM, Alperovitch A, Tehindrazanarivelo A, Biousse V, et al.: Migraine and risk of ischaemic stroke: a case-control study. PMID 1993, 31(307(6899)):289-92.
• [24]Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N: Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 1997, 54(4):362-8.
• [25]Sochurkova D, Moreau T, Lemesle M, Menassa M, Giroud M, Dumas R: Migraine history and migraine-induced stroke in the Dijon stroke registry. Neuroepidemiology 1999, 18(2):85-91.
• [26]Silberstein SD: Shared mechanisms and comorbidities in neurologic and psychiatric disorders. Headache 2001, 41(Suppl 1):S11-7.
• [27]Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science 1996, 13(5281):1516-7.
• [28]Cardon LR, Palmer LJ: Population stratification and spurious allelic association. The Lancet 2003, 361(9357):598-604.
• [29]Laird NM, Horvath S, Xu X: Implementing a unified approach to family-based tests of association. Genet Epidemiol 2000, 19(Suppl 1):S36-42.
• [30]Slager SL, Schaid DJ: Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects. Am J Hum Genet 2001, 68(6):1457-62.
• [31]Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K: The homozygous C677T mutation in the methylenetetrahydofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet 2000, 96:762-764.
• [32]Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES: Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 1996, 58(6):1347-63.
• [33]Rosenberg N, Murata M, Ikeda Y, Opare-Sem O, Zivelin A, Geffen E, Seligsohn U: The frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans. Am J Hum Genet 2002, 70(3):758-62.
• [34]Teng J, Risch N: The relative power of family-based and case-control designs for linkage disequilibrium studies of complex human diseases. II. Individual genotyping. Genome Res 1999, 9(3):234-41.
• [35]Peroutka SJ, Wilhoit T, Jones K: Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology 1997, 49:201-206.
• [36]Lea R, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR: Evidence for allelic association of the dopamine Beta-Hydroxylase Gene (DBH) with Susceptibility to Typical Migraine. Neurogenetics 2000, 3(1):35-40.
• [37]Linda McCarthyC, David HosfordA, John RileyH, Michael Bird, Nicola WhiteJ, Duncan HewettR, Steve PeroutkaJ, Griffiths LR, Boyd PR, Lea RA, Bhatti SM, Hosking LK, Hood CM, Jones KW, Handley AR, Rallan R, Lewis KF, Yeo AJ, Williams PM, Priest RC, Khan P, Donnelly C, Lumsden SM, O'Sullivan J, See CG, Smart DH, Shaw-Hawkins S, Patel J, Langrish TC, Feniuk W, Knowles RG, Thomas M, Libri V, Montgomery DS, Manasco PK, Xu CF, Dykes C, Humphrey PP, Roses AD, Purvis IJ: Single nucleotide polymorphism (SNP) alleles in the Insulin Receptor (INSR) gene are associated with migraine. Genomics 2001, 78(3):135-149.
• [38]Evers S, Koch HG, Husstedt I-W: Plasma homocysteine levels in primary headache. In Headache pathogenesis: monoamines, neuropeptides, purines and nitric oxide. Edited by Olesen J, Edvinsson L. Philadelphia: Lippincott-Raven Publishers; 1997:215-218.
• [39]Stewart WF, Lipton RB, Liberman J: Variation in migraine prevalence by race. Neurology 1996, 47(1):52-9.
• [40]Kara I, Sazci A, Ergul E, Kaya G, Kilic G: Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res 2003, 111(1–2):84-90.
• [41]D'Amico D, Moschiano F, Leone M, Ariano C, Ciusani E, Erba N, Grazzi L, Ferraris A, Schieroni F, Bussone G: Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke? Cephalalgia 1998, 18(9):618-21. discussion 591